Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D

NCT01937598 on ClinicalTrials.gov · last registry update 2017-01-30

A small phase 3 — 16 participants, against a typical 424. The sponsor logged completion for April 2014. Primary outcome, as filed: Incremental Area Under the Plasma Glucose (BG) Concentration-time Profile (AUC). liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Michael A. Nauck
Sponsor type: Other
Enrollment: 16
Started: 2013-08
Primary completion: 2014-04 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Incremental Area Under the Plasma Glucose (BG) Concentration-time Profile (AUC)

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.